Some imminent good news still to come very soon: (Apart from...

Some imminent good news still to come very soon: (Apart from current trials in place)
(Bolding is added by me.)

A) Autosomal Dominant Optic Atrophy (ADOA) program:
 PYC has a pre-IND meeting with the US FDA in late October for this
drug candidate to prepare for the transition to human trials in
patients with ADOA in H1 2024.
(Included a VERY upbeat assesment: The change in protein expression achieved in
these studies has already been demonstrated to rescue the functional deficits of the
disease in human models derived from patients with ADOA (See ASX announcement of 20
October 2023). Together, these data points provide a high degree of conviction in the
potential of the program to be life changing for ADOA patients when clinical trials begin in
the first half of next year.)

B) A third program set to complete Investigational New Drug (IND)-enabling studies
with submission to the FDA anticipated in Q4 2023.

Coupled with ongoing existing trials for RP11, I am still a VERY strong believer in this company and continue to top up at these levels.

Have a great day everyone.
Mal.